Clinical Study Of Anlotinib In Combination With A Generation Of EGFR-TKI In Advanced NSCLC With Slow Progression After TKI Therapy

Objectives: The aim was to compare the clinical efficacy and safety assessment of anlotinib in combination with EGFR-TKI versus EGFR-TKI alone in patients with advanced non-small cell lung cancer with slow disease progression after TKI therapy,measured as T790 M mutation-negative.Methods: After screening and meeting the inclusion criteria to collect 105 all EGFR mutation-positive patients who received the combination treatment regimen,the EGFR mutation-positive non-small cell carcinoma patients were randomly divided into two groups according to 1:1,the experimental group was anlotinib combined with EGFR-TKI and the control group was single-agent EGFRTKI,by means of the chi-square test,Kaplan-Meier survival curve and other analytical statistical methods,the control and analyse the clinicopathological characteristics of lung adenocarcinoma patients in the two groups,the effect of the two different drug regimens on the disease efficacy and on the survival of patients.Results: The disease control rate was higher in the experimental group than in the control group,the serum markers were lower than in the control group,and the progression-free survival was11.00±9.54 months vs9.00 ± 6.73 months in the experimental and control groups respectively(p <0.05).Conclusion: By dividing 105 EGFR-positive NSCLC cases into two groups,anlotinib combined with EGFR-TKI was found to exhibit antitumour activity in overcoming EGFR acquired resistance,outperforming single-agent EGFR-TKI in terms of disease control rate and extending patients’ disease progression-free survival.